Tectonic Therapeutic (TECX) Piper Sandler 36th Annual Healthcare Conference summary

Key scientific and clinical insights

• Compound differentiation is based on isoelectric point, leading to better in vivo potency alignment compared to competitors; similar potency to Lilly, but hard to compare with AZ due to lack of renal blood flow data.

• Biologic compounds are similar in selectivity, but AZ's oral drug has off-target effects and different signaling; drug-drug interactions are possible.

• The compound has a longer half-life (2–3 weeks) than competitors, supporting monthly or biweekly dosing; AZ and Lilly dose more frequently.

• Phase I-B data expected end of Q1 or early Q2, likely before AZ's phase II-B data; 2025 anticipated as a pivotal year for relaxin data across the field.

Clinical trial design and expectations

• Phase I-B study targets a 15–20% reduction in pulmonary capillary wedge pressure and pulmonary vascular resistance, aiming to show improved left heart function and exercise tolerance.

• Study includes both CpcPH and IpcPH populations, aiming for near-even distribution; more IpcPH expected due to enrollment logistics.

• Hemodynamic endpoints in phase I-B are expected to inform phase II, with Six-Minute Walk Test as a key secondary endpoint.

• APEX phase II trial top-line data expected in 2026, with timeline to be refined as enrollment progresses.

Market and regulatory outlook

• Group 2 pulmonary hypertension represents a multi-billion dollar market with no approved therapies; pricing will depend on the treated population.

• Regulatory path is expected to use Six-Minute Walk Test as an approvable endpoint, with exploration of composite and quality-of-life endpoints.

• Investor interest has surged due to strong scientific rationale, large pharma involvement, and unmet need.